<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002820</url>
  </required_header>
  <id_info>
    <org_study_id>1042-0602</org_study_id>
    <nct_id>NCT01002820</nct_id>
  </id_info>
  <brief_title>A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601</brief_title>
  <acronym>0602</acronym>
  <official_title>A Treatment Protocol for Ganaxolone as add-on Therapy in Adult Patients With Uncontrolled Partial-onset Seizures Deriving Benefit From Protocol 1042-0601</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide ganaxolone to those patients deriving significant benefit
      from current treatment in protocol 1042-0601.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety as determined by adverse events</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Epilepsy, Complex Partial</condition>
  <arm_group>
    <arm_group_label>participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects participating in 0602 are receiving ganaxolone for seizure control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganaxolone</intervention_name>
    <description>liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year</description>
    <arm_group_label>participants</arm_group_label>
    <other_name>CCD 1042</other_name>
    <other_name>CAS 383-98323-2</other_name>
    <other_name>3 alpha-hydroxy, 3 beta-methyl, 5 alpha-pregnan-20-one</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects who have completed all study visits from previous protocol 1042-0601 and have
             been deemed eligible by the Investigator as:

          -  having had no major adverse events thought to be drug related

          -  deriving benefit from ganaxolone treatment

          -  be properly informed of the nature and risks of the study and give written informed
             consent prior to study entry

          -  must be willing to use a medically acceptable method of birth control and if female of
             child-bearing potential, have a negative qualitative serum pregnancy test

        Exclusion Criteria:

          -  significant medical or surgical condition at screening or that develops during
             protocol participation that might compromise hematologic, cardiovascular, pulmonary,
             renal, gastrointestinal, or hepatic systems, or other conditions that would place the
             subject under increased risk

          -  unwilling to use a double-barrier method of birth control or submit to a serum
             pregnancy test

          -  history of chronic non-compliance with drug regimens

          -  females currently breastfeeding

          -  AST or ALT levels greater than 3 times the upper limit of normal at screen

          -  Inability to withhold grapefruit or grapefruit products during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Southern California, Dept of Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Dept of Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center, Dept of Neurology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riddle Health Care Center II</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Comprehensive Epilepsy Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <disposition_first_submitted>April 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 20, 2012</disposition_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epileptic Seizures</keyword>
  <keyword>Seizure Disorder</keyword>
  <keyword>Seizures</keyword>
  <keyword>Convulsions</keyword>
  <keyword>Anticonvulsant</keyword>
  <keyword>Anticonvulsive</keyword>
  <keyword>Antiepileptic</keyword>
  <keyword>Ganaxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy, Complex Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

